# DESCRIPTION

## FEDERALLY SPONSORED RESEARCH

- disclose government funding

## BACKGROUND OF THE DISCLOSURE

- introduce base editors

## SUMMARY OF THE DISCLOSURE

- introduce CRISPR/Cas system
- describe adenine base editors
- discuss limitations of ABEs
- motivate need for improved ABEs
- describe existing ABE variants
- introduce TadA7.10 deaminase
- discuss RNA editing activity of ABEs
- hypothesize RNA editing mechanism
- introduce goal of reducing RNA editing

## DEFINITIONS

- define singular and plural forms
- define adenosine deaminase domain
- define base editing
- define base editor
- define Cas9 and variants
- define CRISPR and related terms
- define deaminases
- define adenosine deaminases
- define DNA binding proteins
- define DNA editing efficiency
- define off-target editing frequency
- define RNA editing activity
- define fusion proteins
- define linker
- define low toxicity
- define mutation
- define non-naturally occurring or engineered
- define nucleic acid
- define backbone of guide RNA
- define nucleic acid programmable DNA binding protein
- define promoter
- define recombinant proteins and nucleic acids
- define subject and target site
- define treatment and unique loci
- define variant proteins and wild type proteins

## DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

- introduce adenine base editors with reduced RNA editing footprint
- describe structure-guided mutagenesis approach to design ABE variants
- detail mutations in TadA domains to reduce RNA editing activity
- describe ABE7.10 variants with improved DNA specificity and reduced off-target effects
- discuss off-target activity and napDNAbp-independent editing events
- summarize results of RNA editing and DNA editing experiments
- describe fusion proteins and their applications in targeted genome editing
- describe base editing system
- methods of making base editors
- methods of using base editors
- therapeutic methods for treating genetic diseases
- pharmaceutical compositions comprising base editor fusion proteins

### Adenosine Deaminases

- introduce adenosine deaminases
- describe fusion proteins with substitutions in ecTadA and TadA7.10
- provide exemplary embodiments of adenosine deaminases
- describe mutations in adenosine deaminases
- discuss dimerization of adenosine deaminases
- provide amino acid sequence alignments and substitutions
- describe broadened target sequence compatibility of adenine base editors
- describe adenosine deaminase variants
- describe napDNAbp domains
- explain CRISPR-Cas9 system
- describe napDNAbp-guide RNA complex binding mechanism
- discuss various napDNAbp options
- define Cas protein and Cas9 equivalents
- provide examples of Cas9 and Cas9 equivalents

### Wild Type Cas9 Orthologs

- list Cas9 orthologs
- describe variants of Cas9 orthologs
- introduce dead napDNAbp variants
- describe napDNAbp nickase variants
- introduce other Cas9 variants
- define Cas9 variants
- describe Cas9 equivalents
- introduce CasX and CasY
- discuss other RNA-guided DNA binding proteins
- describe small-sized Cas9 variants
- introduce napDNAbps that recognize non-canonical PAM sequences
- provide specific examples of napDNAbp domains
- introduce Cas9 orthologs
- describe napDNAbp domains
- discuss C2c1, C2c2, and C2c3 proteins
- provide Cas9 domains with altered PAM specificities
- introduce Argonaute proteins
- describe circular permutants of Cas9
- provide examples of circular permutants of Cas9
- define wild type Cas9 orthologs
- describe circular permutant Cas9 variants
- provide exemplary CP-Cas9 sequences
- introduce Cas9 variants with modified PAM specificities
- describe napDNAbp domain comprising SpCas9-NG
- discuss conservative amino acid substitutions
- describe Cas9 protein with increased activity on target sequences
- provide tables of Cas9 clones with modified PAM specificities
- introduce SpCas9-VRQR and SpCas9-VRER variants
- discuss methods for making amino acid substitutions

### Exemplary Fusion Proteins

- describe fusion protein embodiments

### Fusion Protein Architectures

- describe fusion protein architectures
- define Cas9 domains and adenosine deaminases
- describe fusion proteins with linkers
- specify nuclear localization sequences
- provide general architecture of fusion proteins
- describe additional domains and sequences
- introduce reporter genes and epitope tags
- describe linkers and their properties
- provide examples of linkers and their sequences

### Reduced RNA Editing Effects

- define RNA editing effects

### Reduced Off-Target DNA Editing and Indel Frequencies

- motivate reduced off-target effects
- describe intended mutations
- limit indel formation

### Guide Sequences (e.g., Guide RNAs)

- provide guide RNAs for use in editing methods
- design guide sequences with complementarity to target sequences
- describe methods for editing target nucleic acid molecules using guide RNAs and fusion proteins
- specify guide sequence length and complementarity requirements
- select guide sequences to target unique sequences in a genome
- describe tracr mate sequences and their complementarity to tracr sequences
- provide examples of single polynucleotides comprising guide sequences, tracr mate sequences, and tracr sequences
- describe backbone structures recognized by Cas9 proteins and provide exemplary guide RNA sequences

### Methods for Making Fusion Proteins

- describe codon optimization for expression in eukaryotic cells
- explain ancestral sequence reconstruction analysis for improved expression
- introduce vector systems for cloning and expressing base editors
- describe expression of base editor transcripts in prokaryotic or eukaryotic cells
- outline fusion expression vectors for increasing expression and solubility
- summarize suitable expression systems for prokaryotic and eukaryotic cells
- define fusion proteins
- describe editing methods
- summarize application of editing methods
- motivate therapeutic applications
- outline treatment methods
- list diseases and disorders
- describe deaminase-mediated gene editing
- explain numbering of specific positions or residues in sequences
- discuss methods for identifying residues in homologous proteins
- provide examples of suitable diseases and disorders
- outline the instant disclosure
- list genetic disorders
- describe fusion proteins
- motivate methods for making fusion proteins
- outline applications of fusion proteins
- discuss limitations of current methods
- introduce novel approach to making fusion proteins
- list genetic disorders
- describe hypogonadotropic hypogonadism
- summarize ectodermal dysplasias
- outline hypomyelinating leukodystrophies
- categorize immunodeficiency disorders
- group miscellaneous genetic disorders
- list genetic disorders
- describe osteopathia striata with cranial sclerosis
- summarize osteopetrosis autosomal dominant type 1 and 2
- outline various genetic disorders
- describe more genetic disorders
- conclude with zonular pulverulent cataract 3
- outline base editing kit
- provide pharmaceutical compositions
- formulate pharmaceutical compositions
- describe pharmaceutical carriers
- outline administration routes
- discuss controlled release systems
- formulate pharmaceutical kits
- describe articles of manufacture
- introduce delivery methods
- detail non-viral and viral vector delivery systems
- introduce gene therapy methods
- describe viral vectors for gene therapy
- detail AAV vectors and their derivatives
- explain methods for producing and using rAAV vectors
- introduce split intein-based methods for in vivo delivery
- describe kits and cells for gene therapy
- provide examples of cell lines for tissue culture
- discuss advantages of ABEmaxAW variant for adenine base editing
- conclude with general applicability of concepts

## EXAMPLES

### Example 1

- perform RNA editing experiment
- analyze RNA editing results
- test RNA editing activity

### Example 2

- design ABE mutants
- test DNA base editing efficiency
- analyze RNA editing activity

### Example 3

- test applicability of findings in other cell types

### Example 4

- test additional ABEmax mutants

### Example 5

- RNA-Seq analysis of ABEmaxAW

### Materials and Methods for Examples 1-5

- plasmid construction
- mammalian cell culture
- preparation of plasmids for mammalian cell transfection
- mammalian cell lipofection and genomic DNA isolation
- mammalian cell nucleofection
- RNA isolation from mammalian cells
- preparation of genomic DNA and RNA amplicons for high-throughput sequencing

## EQUIVALENTS AND SCOPE

- define scope of patent claims

